Finland is Developing a Model for the Assessment and Reimbursement of Digital Therapies
Finland is developing a model to streamline the adoption of digital healthcare solutions.
Risk-sharing agreements (RSA) are one of the most interesting and debated topics in the Finnish Market Access scene at the moment. Medaffcon has been studying the agreements, their application and experiences in using them and has also been participating in building several risk-sharing agreements in Finland, both in ambulatory care (with Pharmaceutical Pricing Board) and hospital care (with hospitals).
Learn more about RSA’s from the interview with Pekka Männistö from the video below.
Market Access, pricing and reimbursement of medicines in Finland – This article provides information of the market access options and current pricing system in Finland, in ambulatory and hospital care.
Finland is developing a model to streamline the adoption of digital healthcare solutions.
The Swedish Health Economics Association (SHEA) held its annual conference, offering valuable insights into key topics in health economics.
Sweden has introduced a new reimbursement model for orphan drugs, likely to increase treatment options for rare diseases. At the same time, pharmaceutical companies are now expected to provide local evidence.